NEW YORK (GenomeWeb News) – BioTime has raised a further $4 million through the second tranche of a private placement of its common stock and purchase warrants.

The Alameda, Calif.-based firm said that Broadwood Partners and George Karfunkel have each purchased 1.1 million common shares in the firm as well as 1.1 million stock purchase warrants. The warrants are "substantially the same" as BioTime's publicly traded stock purchase warrants, the firm said, and entitles holders to purchase additional common shares at an exercise price of $2 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.